ArticleIntensive care medicine2011
The effects of levosimendan and glibenclamide on circulatory and metabolic variables in a canine model of acute hypoxia.
Article in Intensive care medicine, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 18 citations in OpenAlex.
- Pressure Overload and Right Ventricular Failure: From Pathophysiology to Treatment.Journal of clinical medicine · 2023Review
- Levosimendan in the light of the results of the recent randomized controlled trials: an expert opinion paper.Critical care (London, England) · 2019Review
- Absolute and trend accuracy of a new regional oximeter in healthy volunteers during controlled hypoxia.Anesthesia and analgesia · 2014Article
- Monitoring tissue oxygenation by near infrared spectroscopy (NIRS): background and current applications.Journal of clinical monitoring and computing · 2012Review
- From system to organ to cell: oxygenation and perfusion measurement in anesthesia and critical care.Journal of clinical monitoring and computing · 2012Review
- Year in review in Intensive Care Medicine 2011: I. Nephrology, epidemiology, nutrition and therapeutics, neurology, ethical and legal issues, experimentals.Intensive care medicine · 2012Article
- Levosimendan inhibits release of reactive oxygen species in polymorphonuclear leukocytes in vitro and in patients with acute heart failure and septic shock: a prospective observational study.Critical care (London, England) · 2011Article
- Levosimendan: from coronary care to intensive care?Intensive care medicine · 2011Article
- Levosimendan in pulmonary hypertension and right heart failure.Pulmonary circulationArticle
Corrections and comments
- Commented on by
Authors and funding
5 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo study the effects of pretreatment with levosimendan (LEVO, a Ca²(+)-sensitizer and K (ATP) (+) channel opener) and/or the K (ATP) (+) channel antagonist glibenclamide (GLIB) on systemic hemodynamics, metabolism, and regional gastromucosal oxygenation during hypoxic hypoxemia.
methodsChronically instrumented, healthy dogs (24-32 kg, n = 6 per group, randomized cross-over design) were repeatedly sedated, mechanically ventilated (FiO₂ ~0.3) and subjected to the following interventions: no pretreatment, LEVO pretreatment, GLIB pretreatment, or combined LEVO + GLIB pretreatment, each followed by hypoxic hypoxemia (FiO₂ ~0.1). We measured cardiac output (CO, ultrasonic flow probes), oxygen consumption (VO₂, indirect calorimetry), and gastromucosal microvascular hemoglobin oxygenation (μHbO₂, spectrophotometry). STATISTICS: data are presented as mean ± SEM and compared by one-way ANOVA (direct drug effects within group) and two-way ANOVA (between all hypoxic conditions) both with Bonferroni corrections; p < 0.05.
resultsIn LEVO-pretreated hypoxemia, CO was significantly higher compared to unpretreated hypoxemia. The increased CO was neither associated with an increased VO₂ nor with markers of aggravated anaerobiosis (pH, BE, lactate). In addition, LEVO pretreatment did not further compromise gastromucosal μHbO₂ in hypoxemia. After combined LEVO + GLIB pretreatment, systemic effects of GLIB were apparent, however, CO was significantly higher than during unpretreated and GLIB-pretreated hypoxemia, but equal to LEVO-pretreated hypoxemia, indicating that GLIB did not prevent the increased CO in LEVO-pretreated hypoxia.
conclusionsLEVO pretreatment resulted in improved systemic circulation (CO) during hypoxemia without fueling systemic VO₂, without aggravating systemic anaerobiosis markers, and without further compromising microvascular gastromucosal oxygenation. Thus, LEVO pretreatment may be an option to support the systemic circulation during hypoxia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.